LoRusso, Patricia M <br/><br/>
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Apr 2011 
 - 2502-11 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-10-2745  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abdominal Pain--chemically induced<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anilides--adverse effects<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Neoplasm<br/>Fatigue--chemically induced<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Hedgehog Proteins--antagonists & inhibitors<br/>Humans<br/>Hyponatremia--chemically induced<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Neoplasms--drug therapy<br/>Pyridines--adverse effects<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Signal Transduction--drug effects<br/>Transcription Factors--genetics<br/>Treatment Outcome<br/>Zinc Finger Protein GLI1